WO2006024545A1 - Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp - Google Patents

Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp Download PDF

Info

Publication number
WO2006024545A1
WO2006024545A1 PCT/EP2005/009514 EP2005009514W WO2006024545A1 WO 2006024545 A1 WO2006024545 A1 WO 2006024545A1 EP 2005009514 W EP2005009514 W EP 2005009514W WO 2006024545 A1 WO2006024545 A1 WO 2006024545A1
Authority
WO
WIPO (PCT)
Prior art keywords
flavone
acid
dihydroxy
coumarin
trihydroxy
Prior art date
Application number
PCT/EP2005/009514
Other languages
English (en)
Inventor
Gerrigje Johanna Hageman
Harald Johan Joseph Moonen
Liesbeth Geraets
Aalt Bast
Emiel Frans Maria Wouters
Original Assignee
Stichting Voor De Technische Wetenschappen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Voor De Technische Wetenschappen filed Critical Stichting Voor De Technische Wetenschappen
Publication of WO2006024545A1 publication Critical patent/WO2006024545A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • the invention relates generally to the field of inhibitors of the nuclear enzyme poly(adenosine 5'-diphospho-ribose) polymerase or "PARP" and to medical uses thereof.
  • PARP poly (ADP-ribose) polymerase, EC 2.4.2.30), also known as PARS (for poly(ADP- ribose) synthetase), or ADPRT (for NAD:protein (ADP-ribosyl) transferase (polymerising)), or pADPRT (for poly(ADP-ribose) transferase), is a major nuclear protein of 116 kDa. It is present in almost all eukaryotes, PARP protein is expressed at a high level in many tissues, most notably in the immune system, heart, brain and germ-line cells. Under normal physiological conditions, there is minimal PARP activity. However, DNA damage causes an immediate activation of PARP by up to 500-fold.
  • a number of inflammatory diseases such as bronchitis, lung emphysema, diabetes, rheumatism and chronic infections of the large intestine are characterized by an increase in oxidative stress, which causes damage to cells and tissues.
  • no anti-inflammatory compounds are available for use in preventing, treating an ⁇ /or alleviating chronic diseases or for use on a long-term, i.e. chronic, basis without the risk of inducing serious side-effects.
  • Inhibition of PARP-1 seems to reduce inflammatory processes.
  • the present inventors surprisingly found that a number of naturally occurring compounds inhibit the enzyme PARP-1.
  • NAD + -precursors as PARP-1 inhibitor compound.
  • the NAD + - precursors may be included to ensure optimal NAD + -status and energy metabolism in mitochondria.
  • over-activation of PARP-1 and the subsequent extensive turnover of the substrate NAD + puts a large demand on mitochondrial ATP-production. This may result in an energy crisis due to depletion of NAD + .
  • NAD + levels are reduced, the anaerobic glycolysis, mitochondrial respiration and ATP production are impaired.
  • Resynthesis of NAD + also requires ATP and poses a demand on mitochondrial energy production. Ultimately, these processes may lead to energy failure and necrosis, thus enhancing the oxidative stress and the inflammatory response.
  • the compounds of the invention have a weak to mild PARP-inhibitory activity and are therefore ideally suited for chronic use or for use by patients having specific diseases.
  • the compounds and compositions of the invention are suitable for counteracting the necrosis and inflammatory response of cells for specific groups of patients.
  • the compounds of the invention are described in detail below. It should be understood that many of these natural compounds may exist in plants as a derivative thereof, in the form of covalently bound sugar / oligosaccharide-derivatives, which can be isolated in that form from plants and used as the compounds of the invention, or used in that form in the compositions according to the invention.
  • derivatives of the compounds of the invention encompass, for instance, any glucose or raffinose or other mono- or oligosaccharide derivative of the compounds exemplified herein.
  • the present invention provides compounds of the formula (I) or pharmaceutically acceptable salts, hydrates, esters, solvates, prodrugs, derivatives, metabolites, stereoisomers thereof, for instance for use as anti-inflammatory agents, or for treating, preventing and/or alleviating a disease or disorder involving acute or chronic inflammation, diabetes, atherosclerosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, ischemia and reperfusion damage, endotoxic or haemorrhagic shock, cancer, fibrosis, autoimmune diseases, and/or neuro ⁇ degenerative diseases wherein:
  • A represents the atoms necessary to form a fused 5- to 6-membered ring that is aromatic or nonaromatic, carbocyclic or heterocyclic; and wherein A and any heteroatom therein is unsubstituted or independently substituted with one of non-interfering hydroxyl, alkyl, double bonded oxygen, -OCH 3 , -NH-CO-CH 3 , or
  • R 3 , R 4 , R 5 , R 6 and R 7 are independently chosen from hydrogen, hydroxyl, alkyl, double bounded oxygen, -OCH 3 , or -NH-CO-CH 3 , -O-glucose or -O-raffinose;
  • X is -CHR 8 - or, -NR 9 -, where R 8 is hydrogen, hydroxyl, lower alkyl, -OCH 3 or -NH-CO-
  • CH 3 and R 9 is hydrogen, hydroxyl or lower alkyl
  • Y is -CHR 10 - or, -NR 11 -, where R 10 is hydrogen, hydroxyl, lower alkyl, -OCH 3 or -NH-
  • CO-CH 3 and R 11 is hydrogen, hydroxyl or lower alkyl
  • R 1 when present, is hydrogen, hydroxyl, amino, double bonded oxygen Or-OCH 3 ;
  • R 2 when present, is hydrogen, hydroxyl, amino, double bonded oxygen Or-OCH 3 .
  • these natural PARP-1 inhibitor compounds belong to the family of the xanthines and are generally represented by the formula (II) or by pharmaceutically acceptable salts, hydrates, esters, solvates, prodrugs, derivatives, metabolites or stereoisomers thereof, wherein:
  • R 1 and R 3 when present, are independently chosen from hydrogen and methyl;
  • R 2 , R 4 and R 7 when present, are independently chosen from hydrogen and double bonded oxygen;
  • R 5 when present, is either hydrogen or
  • R 6 when present, is either hydrogen, methyl or
  • the invention relates to the PARP-1 inhibitor compounds of formula (II), which are specifically mentioned in Table 1 , and to their use as a medicament, for the preparation of a medicament, as an anti-inflammatory agent, or as (an additive in) nutraceuticals, functional or medical food.
  • a compound selected from the group consisting of 1 ,7-dimethyluric acid, 1-methyluric acid, 1-methylxanthine, paraxanthine (1 ,7- dimethyl-xanthine), theobromine (3,7-dimethyl-xanthine), xanthine and xanthosine as a medicine, an anti-inflammatory agent, or as (an additive in) nutraceuticals or medical food.
  • these natural PARP-1 inhibitor compounds belong to the family of the coumarines and are generally represented by the formula (III) or by pharmaceutically acceptable salts, hydrates, esters, solvates, prodrugs, derivatives, metabolites or stereoisomers thereof, wherein: R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently chosen from hydrogen, hydroxyl, methyl, methoxy, COOH and -NH-CO-CH 3
  • the invention relates to the PARP-1 inhibitor compounds of formula (III) which are specifically mentioned in Table 2, and to their use as a medicament, for the preparation of a medicament, as an anti-inflammatory agent, or as (an additive in) functional or medical food or nutraceutical.
  • these compounds belong to the family of the flavonoids and are generally represented by the formula (IV)
  • R 1 or R 2 is phenyl, having one to five substituents which are independently chosen from hydrogen and hydroxyl, with the proviso that when R 1 or R 2 is not phenyl, it is hydrogen or hydroxyl; and R 3 , R 4 , R 5 and R 6 , when present, are independently chosen from hydrogen and hydroxyl.
  • solvate includes any combination which may be formed by a compound of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters and the like.
  • a "pro-drug” is considered a derivative of a (natural) compound that after ingestion and/or absorption is metabolized into its active form.
  • rutin - the glycosylated form of quercetin - can be hydrolyzed either by the intestinal microflora or by enzymes produced by intestinal cells or present in organs, into quercetin that is a PARP-inhibitor.
  • caffeine can also be considered a pro-drug.
  • pro-drug connotes pharmacologically acceptable derivatives such as esters, amides and phosphates, such that the resulting in vivo biotransformation product of the derivative is the active drug.
  • the reference by Goodman and Gilman The Pharmacological Basis of Therapeutics, 8th Ed, McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs", p 13-15) describing pro-drugs generally is hereby incorporated.
  • Pro-drugs of the compounds of the invention can be prepared by modifying functional groups present in said component in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent component.
  • Typical examples of pro-drugs are described for instance in WO 99/33795, WO 99/33815, WO 99/33793 and WO 99/33792, all of which are incorporated herein by reference.
  • Pro-drugs are characterized by increased bio-availability and are readily metabolized into the active inhibitors in vivo.
  • stereoisomeric form or "stereoisomere”, as used herein, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess.
  • chemical designation of a compound herein encompasses the mixture of all possible stereochemical)/ isomeric forms, which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemical ⁇ isomeric forms of the compounds of the invention either in pure form or in admixture with each other are intended to fall within the scope of the present invention.
  • substituted or “substituent” is used in the present invention, it is meant to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group, provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
  • compounds of the invention or “PARP-1 inhibitor compounds” or a similar term is used, it is meant to include the compounds of general formula I to VIII and any subgroup thereof.
  • the salts of the compounds according to the invention are those wherein the counter-ion is pharmaceutically or physiologically acceptable.
  • the invention relates to the PARP-1 inhibitor compounds of formula (IV) which are specifically mentioned in Table 3, and to their use as a medicament, for the preparation as a medicament, as an anti-inflammatory agent, or as (an additive in) nutraceuticals, functional or medical food.
  • apigenin (4',5,7-trihydroxy-flavone), baicalein (5,6,7-trihydroxy-flavone), chrysine (5,7-dihydroxy-flavone), daidzein (4',7-dihydroxyisoflavone), fisetin (5- deoxyquercetin; 3,3',4',7-tetrahydroxyflavone), galangin (3,5,7-trihydroxy-flavone), genistein (4',5,7-trihydroxy-isoflavone), gossypetin (3,5,7,8,3',4'-hexahydroxy-flavone), kaempferol (robigenin; 3,4',5,7-tetrahydroxy-flavone), luteolin (3',4',5,7-tetrahydroxy- flavone), morin (2',3,4',5,7-pentahydroxy-fla
  • these PARP-1 inhibitor compounds of formula (I) belong to the family of the anthocyanidins, and are generally represented by the formula (V)
  • R 1 and R 2 are independently chosen from hydrogen, hydroxy! and methoxy.
  • the invention relates to the PARP-1 inhibitor compounds of formula (V) which are specifically mentioned in Table 4, and to their use as a medicament, for the preparation of a medicament, as an anti-inflammatory agent, or as (an additive in) functional or medical food or a nutraceutical.
  • a compound selected from the group consisting of cyanidine, 4'O-methyl-delphinidin, delphinidin, malvidin, pelargonidin, peonidin and petunidin as a medicine, an anti-inflammatory agent, or as (an additive in) nutraceuticals or medical food.
  • the present invention further relates to compounds, belonging to the family of the lignans, generally represented by the formula (Vl), (VII) or (VIII)
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently chosen from hydrogen, hydroxyl or methoxy.
  • the invention relates to the compounds, belonging to the family of the lignans of formula (Vl), (VII) or (VIII) or to other lignans which are specifically mentioned in Table 5 and to their use as a medicament, for the preparation of a medicament, as an anti-inflammatory agent, or as (an additive in) nutraceuticals, functional or medical food.
  • the present invention further relates to the PARP-1 inhibitor compounds represented in Table 6 (polyphenols) for use, for instance, as a medicine, for the preparation of a medicament, as an anti-inflammatory agent, or as (an additive in) nutraceuticals, functional or medical food.
  • Table 6 polyphenols
  • the compounds allo-betulin, betulin, lupeol, nomilin and uvaol belong to the group of triterpenoid compounds (or saponins).
  • mixtures or (pharmaceutical) compositions of these natura) compounds of genera] formula (I) to (VI)I) are provided, which mixtures comprise low doses of each of the ingredients, and which, due to their additive or synergistic effect, are stronger and more effective than a comparable dose comprising only one of these compounds.
  • each PARP-1 inhibitor in a low dose in, for instance, nutraceuticals and food or food supplements, it is possible to avoid toxic effects which may occur much faster when only one inhibitor is used in the higher doses (or concentrations). Also differences between persons with respect to absorption, turn-over and decomposition of certain compounds need to be taken into account only to a lesser extend because a combination of inhibitors belonging to different chemical classes are used. For instance, it is found that a mixture comprising three PARP-inhibiting compounds from Table 3, each in a concentration of 3.33 ⁇ M, shows better PARP- inhibition related anti-inflammatory activity, than one of the individual compounds in a concentration of 10 ⁇ M.
  • the present invention also relates to the use of a composition as a medicament or for the preparation of a medicament, (an additive in) nutraceutical, medical or functional food characterized in that said composition comprises at least one, preferably at least two, more preferably at least three, four, five, six, seven, eight, nine or ten PARP-1 inhibitor compounds chosen from the group of compounds represented in any of Tables 1 to 6, preferably Table 1 , 2, 3, 4 or 6, and even more preferably, said at least one compound is chosen from the group of compounds consisting of adenosine, caffein (1 ,3,7- trimethylxanthine), 1 ,7-dimethyluric acid, hypoxanthine (6-oxypurine), inosine, 1- methyluric acid, 1-methylxanthine, paraxanthine (1 ,7-dimethyl-xanthine), theobromine (3,7-dimethyl-xanthine), theophylline (1 ,3-dimethylxanthine), xanthin
  • the present invention also relates to the use of a composition for the preparation of a medicament, (an additive in) nutraceutical, functional or medical food for treating, preventing and/or alleviating a disease or disorder involving chronic or acute inflammatory processes, characterized in that said composition comprises at least one, preferably at least two, even more preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten poly (ADP-ribose) polymerase (PARP-1) inhibitor compounds chosen from the compounds represented in any of Tables 1 to 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds.
  • PARP-1 poly (ADP-ribose) polymerase
  • the invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one, preferably two, more preferably at least three or four, even more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds as described above, wherein at least one compound is chosen from the group of compounds represented in any of Tables 1 to 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds, and wherein at least another compound is an NAD+ precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2-PYR), 1- methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyri
  • said disease or disorder involving chronic or acute inflammatory processes is chosen from the group of diseases or disorders consisting of diabetes, atherosclerosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), rheumatoid arthritis, (chronic) asthma and heart failure, which diseases are characterized by chronic inflammation of tissues.
  • COPD chronic obstructive pulmonary disease
  • IBD inflammatory bowel disease
  • chronic rheumatoid arthritis
  • the invention relates to the use of any of the PARP-1 inhibitor compounds described herein to inhibit the formation of advanced glycation endproducts (AGEs) in patients with diabetes, and thereby enhance the glucose metabolism via oxidative pathways in these patients (e.g. the mechanism behind this action is that the activity of the enzyme glyceraldehyde-3-phosphate dehydrogenase is enhanced).
  • AGEs advanced glycation endproducts
  • the invention also relates to the use as described above for preventing, treating or alleviating acute inflammation, such as, for instance, acute inflammation due to or as a result of ischemia or reperfusion damage, or due to endotoxic or haemorrhagic shock .
  • the present invention relates to the use of a composition for the preparation of a medicament, (an additive in) nutraceutical, functional or medical food for treating, preventing and/or alleviating cancer, characterized in that said composition comprises at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds chosen from the compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds.
  • the invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds as described above, wherein at least one compound is chosen from the group of compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds, and wherein at least another compound is an NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1 -methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2- PYR), 1-methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl
  • the present invention relates to the use of a composition for the preparation of a medicament, (an additive in) nutraceutical, functional or medical food for treating, preventing and/or alleviating fibrosis, characterized in that said composition comprises at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds chosen from the compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds.
  • the invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds as described above, wherein at least one compound is chosen from the group of compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds, and wherein at least another compound is an NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2- PYR), 1-methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyr
  • the present invention relates to the use of a composition for the preparation of a medicament, (an additive in) nutraceutical, functional or medical food for treating, preventing and/or alleviating autoimmune diseases, preferably autoimmune diseases that cause damage to various organs (e.g. kidneys, lungs, heart, intestines) and tissues (e.g.
  • composition comprises at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds chosen from the compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds.
  • the invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds as described above, wherein at least one compound is chosen from the group of compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds, and wherein at least another compound is an NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2- PYR), 1-methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyr
  • the present invention relates to the use of a composition for the preparation of a medicament, (an additive in) nutraceutical, functional or medical food for treating, preventing and/or alleviating neurodegenerative diseases, characterized in that said composition comprises at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds chosen from the compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds.
  • the invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds as described above, wherein at least one compound is chosen from the group of compounds represented in any of Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds, and wherein at least another compound is an NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2- PYR), 1-methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyr
  • said neurodegenerative diseases is Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis (ALS).
  • the invention relates to the uses of compositions as described above, wherein the inclusion of an NAD + precursor is optional.
  • the invention relates to any of the uses as described above wherein said PARP-1 inhibitor compounds is chosen from the group consisting of adenosine, caffein (1 ,3,7-trimethylxanthine), 1 ,7-dimethyluric acid, hypoxanthine (6- oxypurine), inosine, 1-methyluric acid, 1 -methylxanthine, paraxanthine (1 ,7-dimethyl- xanthine), theobromine (3,7-dimethyl-xanthine), theophylline (1 ,3-dimethyl-xanthine), xanthine, xanthosine, 3-acetamido-coumarin, 6-acetamido-coumarin, auraptene, couma ⁇ n, coumarin-3-carboxylic acid, daphnetin (7,8-dihydroxy-coumarin), 5,7-dihydroxy- 4-methylcoumarin, 6,7-dihydroxy-4-methylcoumarin, esculetin
  • the present invention particularly contemplates the use of a composition for the preparation of a medicament, medical food or nutraceutical, or an additive therefor, for treating, preventing, and/or alleviating a disease or disorder as described herein, wherein said composition comprises at least two compounds, wherein a first compound is a poly (ADP-ribose) polymerase (PARP-1) inhibitor compound as described herein, and wherein a second compound is an NAD + precursor as described herein.
  • PARP-1 poly (ADP-ribose) polymerase
  • PARP-1 poly (ADP-ribose) polymerase
  • the invention relates to any of the uses described above wherein said composition comprises one of the combinations of compounds as represented in Table 7 or 8.
  • said composition comprises a xanthine compound chosen from Table 1 , a coumarine compound chosen from Table 2 and, optionally, an NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2- PYR), 1-methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyridiniums, such as 1- methylpyridinium, 1 ,4-dimethyl-pyridinium; or a pharmaceutical
  • the invention encompasses also the use of a compound chosen from the list consisting of adenosine, caffein (1,3,7-trimethylxanthine), hypoxanthine (6-oxypurine), inosine, theophylline (1 ,3-dimethyl-xanthine), esculetin (6,7-dihydroxycoumarin), 4-hydroxy- coumarin, flavone (2-phenyl-chromone), quercetin (3,3',4',5,7-pentahydroxy-flavone), caffeic acid, catechine, chlorogenic acid, curcumin, ellagic acid, folic acid (vitamin M), 18 ⁇ - glycyrrhetinic acid, L-homocarnosine, isonicotinamide, nicotinamide (niacinamide/vitamin B 3 ), nicotinic acid (niacin/vitamin B 3 ) and purpurin (an anthraquinoid), or a pharmaceutical
  • the pharmaceutically acceptable salts of the compounds according to the invention include the conventional non-toxic salts or the quaternary ammonium salts which are formed, e.g., from inorganic or organic acids or bases.
  • acid addition salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tos
  • Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D- glucamine, and salts with amino acids such a sarginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quatemized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl-bromides and others.
  • Other pharmaceutically acceptable salts include the sulfate salt ethanolate and sulfate salts.
  • the compounds and compositions described herein can be used to prevent or treat the onset or progression of any disease or condition related to PARP activity in mammals, especially humans. Such conditions include acute and chronic inflammation, endotoxic shock, diabetes, arthritis, cardiac ischemia, retinal ischemia, skin aging, acute stroke, chronic and acute pain, hemorrhagic shock, and others.
  • the compounds and compositions described herein may be used for inhibiting an inflammatory response by prevention of necrosis.
  • a patient following the symptoms of a stroke, a patient can be administered one or more compounds described herein to prevent or minimize damage to the brain.
  • the compounds and compositions may be used for the prevention and/or the therapy of ischaemia and reperfusion damage.
  • inventions include the use of the compounds or compositions described herein for the inhibition of inflammatory processes mediated by NF- ⁇ B or for the inhibition of stress-response processes mediated by AP-1.
  • the invention also relates to the use of the compounds or compositions of the invention for inhibition of NF-/d3-mediated inflammatory processes in chronic inflammatory diseases (for instance, but not limited to diabetes, atherosclerosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (IBD), rheumatoid arthritis), or for the prevention of bone resorption in postmenopausal osteoporosis and due to implant particles/debris.
  • chronic inflammatory diseases for instance, but not limited to diabetes, atherosclerosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (IBD), rheumatoid arthritis
  • chronic inflammatory diseases for instance, but not limited to diabetes, atherosclerosis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases
  • the invention also relates to the use of the compounds or compositions described herein for preventing, treating and/or alleviating COPD to reduce the consequent muscle weakness and/or muscle breakdown effects. Still other embodiments of the invention relate to the use of the compounds or compositions described herein for preventing apoptosis in non-cancerous cells.
  • the compounds and compositions of the invention are also useful for prevention of skin-aging, especially increased break-down of collagen.
  • Other PARP related conditions or diseases treatable by the compounds or compositions described herein include traumatic injury to the central nervous system, such as brain and spinal cord injuries, and the neuronal degradation associated with traumatic injury to the central nervous system.
  • Related conditions and diseases treatable by methods of the present invention include vascular strokes, cardiac ischemia, cerebral ischemia, cerebrovascular disorders such as multiple sclerosis, and neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases.
  • Patients with symptoms of Alzheimer's, Huntington's, or Parkinson's disease can be treated with compounds of the present invention to halt the progression of the disease or alleviate symptoms.
  • PARP inhibitors may also be used to treat patients suffering from cancer. For instance, cancer patients can be administered the present compounds in order to augment the anti-tumour effects of chemotherapy.
  • preventing, treating and/or alleviating any of the diseases mentioned herein is accomplished by the administration of a therapeutically effective amount of the compounds or compositions of the invention are administered to a patient in need thereof.
  • patient relates to mammals, especially humans.
  • the invention thus also relates to a method for preventing, treating and/or alleviating an inflammatory process in a patient, as well as methods for preventing, treating and/or alleviating cancer, fibrosis, autoimmune diseases or neurodegenerative diseases in a patient, comprising administering to a patient a therapeutically effective amount of a compound chosen from the list consisting of adenosine, caffein (1 ,3,7-trimethylxanthine), 1 ,7-dimethyluric acid, hypoxanthine (6- oxypurine), inosine, 1-methyluric acid, 1-methylxanthine, paraxanthine (1 ,7-dimethyl- xanthine), theobromine (3,7-dimethyl-xanthine), theophylline (1 ,3-dimethylxanthine), xanthine, xanthosine, 3-acetamido-coumarin, 6-acetamido-coumarin, auraptene, coumarin,
  • the method for preventing, treating and/or alleviating inflammatory process, cancer, fibrosis, autoimmune diseases or neurodegenerative diseases comprises administering to a patient a therapeutically effective amount of NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1- methyl-2-pyridone-5-carboxamide (2-PYR), 1-methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyridiniums, such as 1-methylpyridinium, 1 ,4-dimethyl-pyridinium; or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said NAD + precursors.
  • NAD + precursor preferably chosen from the group consisting of nicot
  • the present invention relates to a medicament, (an additive in) a nutraceutical or a medical food for treating, preventing and/or alleviating a disease or disorder involving chronic or acute inflammatory processes
  • a first compound is a poly (ADP-ribose) polymerase (PARP-1 ) inhibitor compound chosen from the group consisting of caffein (1 ,3,7-trimethylxanthine), 1 ,7-dimethyluric acid, 1- methyluric acid, 1-methylxanthine, paraxanthine (1 ,7-dimethyl-xanthine), theobromine (3,7-dimethyl-xanthine), theophylline (1,3-dimethylxanthine), 3-acetamido-coumarin, 6- acetamido-coumarin, auraptene, coumarin, coumarin-3-carboxylic acid, daphnetin (7,8- dihydroxy-coumarin), 5,7-dihydroxy-4-
  • PARP-1 poly (ADP
  • the PARP-1 inhibitor compounds of the present invention will normally be formulated into a pharmaceutical composition in accordance with pharmaceutical practice.
  • PARP-1 inhibitors may be administered by any route that drugs are conventionally administered.
  • routes of administration include intraperitoneal, intravenous, intramuscular, subcutaneous, intrathecal, intratracheal, intraventricular, oral, buccal, rectal, parenteral, intranasal, transdermal, intradermal or by inhalation. Administration may be systemic or localized.
  • compositions described herein may be administered in pure form, combined with other active ingredients, or combined with pharmaceutically acceptable nontoxic excipients or carriers.
  • Oral compositions will generally include an inert diluent carrier or an edible carrier.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such as sucrose or
  • dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings, and flavorings.
  • sucrose as a sweetening agent
  • certain preservatives dyes, colorings, and flavorings.
  • the carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Alternative preparations for administration include sterile aqueous or nonaqueous solutions, suspensions, and emulsions.
  • nonaqueous solvents are dimethylsulfoxide, alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include mixtures of alcohols and water, buffered media, and saline.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases, and the like.
  • Preferred methods of administration of the present compounds to mammals include intraperitoneal injection, intramuscular injection, and intravenous infusion.
  • Various liquid formulations are possible for these delivery methods, including saline, alcohol, DMSO, and water
  • the term "therapeutically effective amount” is meant to refer to an amount of a compound or composition of the present invention that will elicit a desired therapeutic or prophylactic effect or response when administered according to the desired treatment regimen.
  • the PARP-inhibiting compounds or compositions including nutraceuticals, functional and medical foods of the invention are administered to a subject, e.g. a patient in such a dose that a plasma concentration between about 1 nM and 10 mM of the active ingredients, including metabolites, is obtained.
  • said plasma concentration is between 0.1 and 50 ⁇ M or between 0.5 and 40 ⁇ M, more preferably, said plasma concentration is between 1 and 30 ⁇ M, or between 2 and 20 ⁇ M or between 5 and 15 ⁇ M or about 10 ⁇ M per compound. It will be appreciated by the person skilled in the art that plasma concentrations above 100 ⁇ M per compound toxic effects may occur for some of these compounds in normal human cells.
  • the NAD + precursors in the compositions according to the invention are administered to a subject, e.g. a patient in such a dose that a plasma concentration between about 1 nM and 100 mM of the active ingredients, including metabolites, is obtained.
  • a plasma concentration between about 1 nM and 100 mM of the active ingredients, including metabolites, is obtained.
  • said plasma concentration is between 10 nM and 10 mM or between
  • said plasma concentration is between 1 ⁇ M and 100 ⁇ M, or between 2 and 50 ⁇ M or between 5 and 25 ⁇ M or about 10 ⁇ M per compound.
  • whole blood (containing blood cells and plasma) concentrations are in the millimolar range.
  • Plasma concentrations above 50 ⁇ M of compounds may exert toxic effects in normal human cells.
  • the compounds or composition is provided in a unit dosage form, for example a tablet, capsule or metered aerosol dose, so that a single dose is administered to the subject, e.g. a patient.
  • Each dosage unit for oral administration contains suitably from about 0.1 mg to about 60 mg/Kg, preferably from about 0.3 mg to about 30 mg/Kg and even more preferably from about 0.6 mg to about 6.25 mg/Kg of a compound or a pharmaceutically acceptable salt thereof, all measured as the free base per weight expressed in Kg of the subject, e.g. a patient, receiving said compound.
  • Each dosage unit for parenteral administration contains suitably from 0.1 mg to 60 mg/Kg, of the compound or a pharmaceutically acceptable salt thereof.
  • a dose unit may contain about 5 to 1000 mg, or 50 to 500 mg, or 100 to 250 mg of an active ingredient.
  • Each dosage unit for intranasal administration contains suitably 1-400 ⁇ g and preferably 10 to 200 ⁇ g per activation.
  • a dry powder inhalation dose could contain 1-1000 micrograms per dose unit.
  • a topical formulation contains suitably 0.001 to 5.0% of a present compound.
  • the man skilled in the art knows how to define or calculate the actual dose to be administered to a patient.
  • the dosage unit for oral administration of the NAD + precursor contains between about 0.1 mg to about 60 mg/Kg, preferably from about 0.3 mg to 30 mg/Kg, even more preferably from about 0.6 mg to about 6.25 mg/Kg, more preferably from about 0.9 mg to about 3.6 mg/Kg and even more preferably from about 1.2 mg to about 2.4 mg/Kg.
  • a dose unit may contain about 0.5 to 500 mg, or about 1 to 250, or about 5 to 200 mg, or about 10 to 100 mg, or 25 to 75 mg, or about 50 mg of an active ingredient.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit the desired activity. These daily doses can be given as a single dose once daily, or can be given as two or more smaller doses at the same or different times of the day which in total give the specified daily dose. Preferably, the active ingredient is administered once or twice a day. It is contemplated that both active agents would be administered at the same time, or very close in time. Alternatively, one compound could be taken in the morning and one later in the day. Or in another scenario, one compound could be taken twice daily and the other once daily, either at the same time as one of the twice-a-day dosing occurred, or separately. Preferably both compounds would be taken together at the same time and be administered as an admixture.
  • the second compound is administered simultaneously with, separate from or sequential to said first compound.
  • the daily maintenance dose can be given for a period clinically desirable in the patient, for example from 1 day up to several years (e.g. for the mammal's entire remaining life); for example from about (2 or 3 or 5 days, 1 or 2 weeks, or 1 month) upwards and/or for example up to about (5 years, 1 year, 6 months, 1 month, 1 week, or 3 or 5 days).
  • Administration of the daily maintenance dose for about 3 to about 5 days or for about 1 week to about 1 year is typical.
  • Other constituents of the liquid formulations may include preservatives, inorganic salts, acids, bases, buffers, nutrients, vitamins, or other pharmaceuticals such as analgesics or additional PARP inhibitors.
  • Compounds of the present invention also may take the form of a pharmacologically acceptable salt, hydrate, solvate, or metabolite.
  • Pharmacologically acceptable salts include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, nitric acid, methanesulphonic acid, ethanesulfonic acid, p-toluenesulfonic acid, naphtalenesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like.
  • acids of the invention include an acidic function, such as a carboxy group
  • suitable pharmaceutically acceptable cation pairs for the carboxy group are well known to those skilled in the art and include alkaline, alkaline earth, ammonium, quaternary ammonium cations and the like.
  • compositions of the invention may be used as nutraceuticals, functional or medical food, or as additives in said nutraceuticals, functional or medical food
  • the invention also relates to (additives for) nutraceuticals, functional or medical food comprising at least one or two, preferably at least three or four, more preferably at least five, six, seven, eight, nine or ten PARP-1 inhibitor compounds identified in the present invention, i.e. any of the compounds represented in Tables 1 , 2, 3, 4, 5 and 6, or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said compounds.
  • the (additives in) nutraceuticals, functional or medical food according to the invention comprise a therapeutically effective amount of NAD + precursor, preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan; trigonelline derivatives; metabolites and pyrolysis products of trigonelline, such as for instance nicotinamide, 1-methylnicotinamide, 1-methyl-2-pyridone-5-carboxamide (2-PYR), 1- methyl-4-pyridone-5-carboxamide (4-PYR), and alkyl-pyridiniums, such as 1-methyl- pyridinium, 1 ,4-dimethyl-pyridinium; or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, derivative, metabolite or stereoisomer of any of said NAD + precursors.
  • NAD + precursor preferably chosen from the group consisting of nicotinic acid (NIACIN); L-tryptophan;
  • nutraceutical denotes usefulness in both the nutritional and pharmaceutical field of application. Therefore, the novel nutraceutical composition can be used as a supplement to food and beverages, and as pharmaceutical formulation for enteral or parenteral application, which may be solid formulations such as capsules or tablets, or liquid formulations such as solutions or suspensions as described above. As will be evident from the foregoing, the term nutraceutical composition also comprises food and beverages containing PARP-1 inhibitors as well as supplement compositions containing both active ingredients.
  • the nutraceutical of the present invention contains PARP-1 inhibitors in an amount sufficient to administer to a subject a dosage as specified above.
  • Another embodiment provides a food or beverage, preferably fit for human consumption, which is comprised of a nutraceutical and a flavoring agent, wherein the nutraceutical is comprised of an extract from an agricultural product.
  • Nutraceuticals whether in the form of a liquid extract or dry composition, are edible and may be eaten directly by humans, but are preferably provided to humans in the form of additives or nutritional supplements e.g., in the form of tablets of the kind sold in health food stores, or as ingredients in edible solids, more preferably processed food products such as cereals, breads, tofu, cookies, ice cream, cakes, potato chips, pretzels, cheese, etc., and in drinkable liquids e.g., beverages such as milk, soda, sports drinks, and fruit juices.
  • a method is provided for enhancing the nutritional value of a food or beverage by intermixing the food or beverage with a nutraceutical in an amount that is effective to enhance the nutritional value of the food or beverage.
  • Another embodiment provides a method for enhancing the nutritional value of a food or beverage which comprises intermixing a food or a beverage with a nutraceutical to produce a nutritionally-enhanced food or beverage, wherein the nutraceutical is intermixed in an amount effective to enhance the nutritional value of the food or beverage, wherein the nutraceutical is comprised of an extract from a crop comprising the PARP-1 inhibitors of the present invention, and wherein the nutritionally-enhanced food or beverage may further comprise a flavoring agent.
  • Preferred flavoring agents include sweeteners such as sugar, corn syrup, fructose, dextrose, maltodextrose, cyclamates, saccharin, phenyl ⁇ alanine, xylitol, sorbitol, maltitol, and herbal sweeteners e.g., Stevia.
  • the nutraceuticals described herein are intended for human consumption and thus the processes for obtaining them are preferably conducted in accordance with Good Manufacturing Practices (GMP) and any applicable government regulations governing such processes. Especially preferred processes utilize only naturally derived solvents.
  • the nutraceuticals described herein preferably contain relatively high levels of health- enhancing substances Nutraceuticals may be intermixed with one another to increase their health-enhancing effects.
  • Medical foods are not meant to be used by the general public and are not available in stores or supermarkets. Medical foods are not those foods included within a healthy diet to decrease the risk of disease, such as reduced-fat foods or low-sodium foods, nor are they weight loss products.
  • a physician prescribes a medical food when a patient has special nutrient needs in order to manage a disease or health condition, and the patient is under the physician's ongoing care. The label must clearly state that the product is intended to be used to manage a specific medical disorder or condition.
  • An example of a medical food is nutritionally diverse medical food designed to provide targeted nutritional support for patients with chronic inflammatory conditions. Active compounds of this product are for instance one or more of the compounds described herein. Functional foods may encompass those foods included within a healthy diet to decrease the risk of disease, such as reduced-fat foods or low- sodium foods, or weight loss products.
  • Medical foods are especially contemplated for improving recovery after a hemorrhagic shock.
  • Patients in need of surgery may be treated daily with the medical foods of the invention, in order to enhance recovery and reduction of time spent in the hospital.
  • the patients may be treated before and/or after surgery with the medical foods of the invention.
  • the present invention contemplates a food or beverage comprising a nutrace ⁇ t ⁇ ca ⁇ according to the invention.
  • composition encompasses plant extracts comprising at least one and preferably at least two of the PARP-1 inhibitor compounds of the present invention.
  • pharmaceutical composition encompasses plant extracts comprising at least one and preferably at least two of the PARP-1 inhibitor compounds of the present invention.
  • plant extracts relates to an extract of a plant, plant seeds, roots, sprouts or plant cells comprising at least one and preferably at least two PARP-1 inhibitor compounds as described herein.
  • An extract of a plant may be obtained by withdrawing by expression, distillation, or any other mechanical or chemical process, whereby the activity of the PARP-1 inhibitor compounds remains essentially intact.
  • an extract relates to a concentrated preparation of a vegetable drug obtained by removing the active constituents, i.e. the PARP-1 inhibitor compounds, therefrom with a suitable menstruum, evaporating all or nearly all the solvent and adjusting the residual mass or powder to a prescribed standard.
  • extracts are prepared in three forms, semiliquid or of syrupy consistency, pilular or solid and as dry powder.
  • the extract is comprised of a substance selected from the group consisting of carbohydrate, sugar, fat, protein, amino acid, vitamin, anti-oxidant, polyphenol, caffeic acid, ferulic acid, and chlorogenic acid, more preferably an anti-oxidant.
  • the flavoring agent is a sweetener.
  • the solvent may be comprised of a liquid selected from the group consisting of water, an aqueous salt solution, ethanol, isopropanol, n-butanol, glycerol, carbon dioxide, acetone, methyl ethyl ketone, ethyl acetate, propyl acetate, butyl acetate, and mixtures thereof.
  • the plant extracts according to the invention may be used for the preparation of (an additive in) a functional or medical food or nutraceutical for treating, preventing and/or alleviating a disease as defined herein, e.g. chronic or acute inflammatory processes, diabetes, atherosclerosis, chronic obstructive pulmonary disease, IBD, rheumatoid arthritis, ischemia and reperfusion damage, endotoxic or haemorrhagic shock, cancer, fibrosis, autoimmune disease or neurodegenerative disease.
  • a disease e.g. chronic or acute inflammatory processes, diabetes, atherosclerosis, chronic obstructive pulmonary disease, IBD, rheumatoid arthritis, ischemia and reperfusion damage, endotoxic or haemorrhagic shock, cancer, fibrosis, autoimmune disease or neurodegenerative disease.
  • a disease e.g. chronic or acute inflammatory processes, diabetes, atherosclerosis, chronic obstructive pulmonary disease, IBD, rhe
  • Table 9 represents results of PARP-activity measurements. Therefore, pure PARP-1 was incubated with the substrate NAD + and the PARP-inhibitors to be tested. The names of test-compounds are depicted in the table. In each of the experiments, 3-aminobenzamine (3-AB) was used as a control. 3-aminobenzamide is a frequently used synthetic PARP-1 inhibitor. Each compound was tested at least 3 times and most were tested 6 times. The data presented are the mean of 3-6 replications. In Table 9, the % inhibition after incubation of the respective PARP-inhibitor test- compounds (at a concentration of 100 ⁇ M, or indicated if different) with pure PARP-1 is designated.
  • the activity of the PARP-1 inhibitor test compounds were measured in a PARP inhibition ELISA (ELISA) and in a cell culture NAD+ assay (Cell assay).
  • ELISA PARP inhibition ELISA
  • Cell assay cell culture NAD+ assay
  • Patients suffering from chronic inflammatory diseases such as COPD are treated with specific nutritional supplements or preparations that contain a combination of a NAD + - precursor and one or more of the PARP-inhibiting compounds listed in Tables 1-4 and 6.
  • mice are repeatedly challenged with LPS (E coli, serotype 055: B5: Sigma Chemical Co.) twice a week for a period of 12 wk by intratracheal instillation to induce a chronic pulmonary inflammation.
  • Sham mice are instilled intratracheally with LPS-free sterile 0.9% NaCI, whereas control mice receive no treatment.
  • Intratracheal instillation is performed by a nonsurgical technique.
  • mice are anesthetized by intraperitoneal injection of xylazin/ketamin. A volume of 50 ⁇ l is instilled intratracheally via a canule, followed by 0.1 ml of air.
  • mice After intratracheal treatment, the mice are kept in an upright position for 10 min to allow sufficient spreading of the fluid throughout the lungs. Mice are killed 1 wk after the final intratracheal instillation.
  • Saline group (n 10): intratracheal instillation of 50 ⁇ l sterile saline; mice are killed 1 wk after the final intratracheal instillation.
  • Control group (n 5): age-matched control mice.
  • Single PARP-inhibitors or combinations of several natural PARP-inhibitors is administered to a group of 10 mice. For each group, a group of 5 pair-fed mice is formed that receives the standard lab chow (SRM-A; Hope Farms, Woerden, the Netherlands) and are treated with LPS as described above.
  • Morin (M), fisetin (F), theobromine (T), 1 ,7-dimethylxanthine (X) and delphinidin (C) are added to standard lab chow ensuring an intake of PARP- inhibiting compounds by the mice in the range of 5-50 mg/kg/day (for each compound) with plasma concentrations between 1-10 ⁇ M.
  • 5 mice are sham-treated with LPS-free saline and 5 mice are treated with LPS as described above.
  • Example 3 Amelioration of vascular dysfunction in diabetes Patients with diabetes experience problems with vascular function that cause a dysfunction of important organs and tissues (heart, kidneys, retina, neurons) and problems with blood flow through peripheral tissues in toes and feet that can lead to loss of these tissues (amputation of toes or a foot).
  • Human whole blood was acquired by venapunction in blood tubes containing EDTA or heparin. Immediately hereafter, or after storage at 4 0 C or 37 0 C for a maximum of 8 hours, the blood was aliquoted into cell culture wells and diluted 4 times with culture medium.
  • the diluted blood was then pre-incubated for 30 min at 37 0 C with potential PARP-1 inhibiting compounds or mixtures thereof (see Tables 1-4 and 6). Subsequently, LPS was added (final concentration between 1 ng/ml and 1 ⁇ g/ml) and the blood was incubated for 16 or 24 hours at 37 0 C.
  • cytokine levels e.g. IL-6
  • Figure 1 is a summary of the anti-inflammatory activity of different PARP-1 inhibitors and combinations of PARP-1 inhibitors in human blood from a patient with diabetes.
  • diabetes patients daily receive specific nutritional supplements or preparations that contain a combination of a NAD + -precursor and one or more of the PARP-inhibiting compounds listed in Tables 1-4 and 6.
  • mice are treated with streptozotocin (240 mg/kg IP) or vehicle (citrate buffer). Blood glucose is monitored weekly; hyperglycemia is defined as nonfasting blood glucose level >11 mmol/l. When hyperglycemia is established, mice are fed the expermimental diet as indicated below.
  • the effect of a combination of PARP-inhibitors is studied as follows: Each compound or combination of compounds is administered to a group of 10 mice. Of each diet group, 5 mice are sham-treated with vehicle and these serve as controls for potential side effects of the administered natural PARP-inhibitors and 5 mice are treated with streptozotocin.
  • mice For each experimental diet group, a group of 5 pair-fed mice is formed that receive the standard lab chow (SRM-A; Hope Farms, Woerden, the Netherlands) and are also treated with streptozotocin as described above. Morin (M), fisetin (F), 1 ,7-dimethylxantine (X), theobromine (T), delphinidin (D) are added to standard lab chow ensuring an intake of each compound in the range of 5-50 mg/kg/day with plasma concentrations of free plus conjugated compounds in the range of 1-10 ⁇ M.
  • SRM-A Standard lab chow
  • Morin (M) fisetin
  • X 1 ,7-dimethylxantine
  • T theobromine
  • D delphinidin
  • mice After 4 weeks on the experimental diet, mice are killed, blood collected and aorta is excised as described by Knaapen et al. (Knaapen et al. (2001) "Ambient particulate matter induces relaxation of rat aortic rings in vitro.” Hum-Exp-Toxicol. 20(5): 259-65). Aortic rings of approx. 2 mm are transferred into organ baths and vascular function is determined by measuring relaxation with acetylcholine (Ach; 1x10 '6 mol/l) after precontracting with phenylephrine (PE; 3x10 "6 mol/l).
  • Ach acetylcholine
  • PE phenylephrine
  • mice of an age of 5 wk (10/group) are fed a standard lab chow (SRM-A; Hope Farms, Woerden, the Netherlands) for a period of 10 weeks to which Morin (M), fisetin (F), theobromine (T), 1 ,7-dimethylxantine (X), delphinidin (D) are added in such amounts that the intake of the mice is in the range of 5-50 mg/kg/day with plasma concentrations of free plus conjugated compounds in the range of 1-10 ⁇ M.
  • SRM-A Standard lab chow
  • mice receives the standard diet without additions.
  • Wild-type mice (10/group) receive the experimental diets and serve as controls for potential side effects.
  • mice After 12 weeks, mice are killed and the arterial tree collected as described by Curfs et al. (2004).
  • the number of atherosclerotic lesions per aortic arch and mean aortic plaque size, infiltrations of lymphocytes and macrophages in atherosclerotic plaques are determined as described by Curfs et al. (2004).
  • lmmunehistochemical evaluation of PARP-activation in endothelial cells was done as described elsewhere (Hageman et al. (2003) "Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients.” Free-Radic-Biol-Med. 35(2): 140-8), using a rabbit-anti-poly(ADP-ribose). Transcription of TNF-alpha, IL-1/? and MIP-2 was determined in aortic tissues by RT-PCR.
  • mice After 12 weeks, mice develop mild atherosclerosis with predominantly initial lesions. Addition of 2 or more PARP-inhibitors to the standard diet reduces the number of atherosclerotic lesions and the plaque size, and reduces the production of pro ⁇ inflammatory cytokines of aortic tissues (Table 12). No pathological effects are observed of the experimental diets in wild-type mice.
  • Example 5 Reduction of inflammation and improved recovery after a hemorrhagic shock
  • Shock is a state in which adequate perfusion to sustain the physiologic needs of organ tissues is not present. Many conditions, including sepsis, blood loss, impaired autoregulation, and loss of autonomic tone, may produce shock or shock-like states. In hemorrhagic shock, blood loss exceeds the body's ability to compensate and provide adequate tissue perfusion and oxygenation. This frequently is due to trauma, but it may be caused by spontaneous hemorrhage, surgery, and other causes.
  • the patients experience an enhanced recovery with a reduction of time spent in hospital up to 20%.
  • the animals are placed in supine position and allowed to breath spontaneously.
  • body temperature is maintained at 37°C with an infrared heating lamp controlled by a thermo analyzer system (Hugo Sachs Elektronik, March-Hugstetten, Germany) connected to a rectal probe.
  • the skin over the left femoral area is shaved and disinfected with povidon iodine.
  • rats are subjected to hemorrhage by withdrawing blood in quantities of 2.1 ml/100 g body weight (representing approx. 30-40% of circulating volume) at a rate of 1 mL/min. Both heart rate and blood pressure are monitored during 10 minutes. 10 minutes after induction of shock, the canule is removed and the incision is ligated.
  • Each compound or combination of compounds is administered to a group of 10 rats. Of each group, 5 rats are sham-treated (no blood withdrawn) and these serve as controls for potential side effects of the administered PARP-inhibitors.
  • Morin (M), fisetin (F), 1 ,7-dimethylxantine (X), theo- bromine (T), delphinidin (D) are administered intravenously directly after induction of the shock in the range of 5-50 mg/kg to achieve plasma concentrations of free plus conjugated compounds in the range of 1-10 ⁇ M.
  • Parameters measured are PARP-activation and apoptosis of the liver, levels of TNF-alpha, IL-6 and IFN-gamma in plasma, and infiltration of neutrophils (MPO activity) in the lungs.
  • Example 6 Reduction of tissue damage and inflammation in a renal ischemia- reperfusion model Ischemia is the condition suffered by tissues and organs when deprived of blood flow, which are mostly the effects of inadequate nutrient and oxygen supply.
  • Reperfusion injury refers to the tissue damage inflicted when blood flow is restored after an ischemic period of more than about ten minutes. Ischemia and reperfusion can cause serious brain damage in stroke or cardiac arrest.
  • the patients experience an enhanced recovery after the operation and a reduction of time spent in hospital up to 20%.
  • mice are anesthetized with sodium pentobarbital (100 mg/kg ip). Body temperature is maintained at 38 0 C by a heating pad. The skin over the abdomen is shaved and desinfected with povidone iodine solution. Under aseptic conditions, a 1.0-cm-long midline abdominal incision is made. Ischemia is induced by applying a nontraumatic vascular clamp to the left renal pedicle for 45 min. After 3 min, the kidney is inspected for signs of ischemia; subsequently, the wound is covered with cotton soaked in sterile phosphate-buffered saline (PBS). After 45 min ischemia, reperfusion is induced by removal of the clamp. The left kidney is inspected for restoration of blood flow and the contralateral kidney is removed and stored for further analysis. The wound is closed in two layers.
  • PBS sterile phosphate-buffered saline
  • mice are sacrificied. Organs and blood are collected for further analysis. Neutrophils are counted by examining 20 fields of vision per kidney section (3-4 sections per kidney) at 20Ox magnification in a blinded fashion. The presence of internucleosomal DNA cleavage in kidneys is investigated with a commercial ligase- mediated (LM)-polymerase chain reaction (PCR) assay kit (Apoalert, Clontech, Palo Alto,
  • CA Reverse Transcriptase
  • mice are sham-treated (no clamp) and these serve as controls for potential side effects of the administered PARP-inhibitors.
  • Morin (M), fisetin (F), 1 ,7- dimethylxantine (X), theobromine (T), delphinidin (D) are administered intravenously 15 min before removal of the clamp at doses of 10-50 mg/kg to achieve plasma concentrations of free plus conjugated compounds in the range of 1-10 ⁇ M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'au moins deux composés, identifiés comme étant des inhibiteurs de PARP-1, dont le premier est un composé naturel de formule générale (II) à (V), et le second est un précurseur de NAD+, dans la préparation de médicaments et d'aliments fonctionnels ou nutraceutiques. Par ailleurs, l'invention concerne d'utilisation de ces composés ou de compositions pharmaceutiques renfermant ces composés comme agent anti-inflammatoire pour traiter l'inflammation aiguë ou chronique dans certains troubles ou maladies.
PCT/EP2005/009514 2004-09-03 2005-09-05 Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp WO2006024545A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04447196.9 2004-09-03
EP04447196 2004-09-03
EP04447238 2004-10-28
EP04447238.9 2004-10-28

Publications (1)

Publication Number Publication Date
WO2006024545A1 true WO2006024545A1 (fr) 2006-03-09

Family

ID=35355317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009514 WO2006024545A1 (fr) 2004-09-03 2005-09-05 Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp

Country Status (1)

Country Link
WO (1) WO2006024545A1 (fr)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042441A2 (fr) * 2004-10-22 2006-04-27 Dsm Ip Assets B.V. Nouveaux agents de prevention et de traitement de troubles associes a une neurotransmission deficiente
WO2007132893A1 (fr) * 2006-05-17 2007-11-22 Arkray, Inc. Suppresseur d'expression de mcp-1 et agent d'amélioration des maladies inflammatoires, produit pharmaceutique, complément, aliment, boisson ou additif alimentaire comprenant ledit suppresseur
WO2008021368A2 (fr) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions et méthodes de neuroprotection
WO2008024893A2 (fr) * 2006-08-23 2008-02-28 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procédé de traitement ou de prévention d'une maladie associée au stress oxydatif
JP2008120729A (ja) * 2006-11-13 2008-05-29 Kao Corp Ｆｘｒ活性化剤
WO2008086403A1 (fr) * 2007-01-09 2008-07-17 Unigen Pharmaceuticals, Inc. Chromones utilisées comme agents thérapeutiques
WO2008104920A1 (fr) * 2007-02-28 2008-09-04 Trigendo Sp. Z O.O. Utilisation de composés de pyridinium quaternaires pour la vasoprotection et/ou l'hépatoprotection
WO2008012666A3 (fr) * 2006-07-28 2008-09-04 Indena Spa Procédés de traitement et de prévention d'une mucite
WO2008115723A1 (fr) 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition et procédé pour le traitement du diabète et de perturbations du métabolisme
WO2010066641A1 (fr) * 2008-12-11 2010-06-17 Unilever Plc Composition orale
EP2243474A1 (fr) * 2009-04-23 2010-10-27 King Saud University Effet prospectif de thymoquinome dans la sepsie
CN101991566A (zh) * 2010-11-26 2011-03-30 中国人民解放军第二军医大学 落叶松脂醇在制备抗自身免疫病和抗移植排斥疾病药物中的应用
WO2011058367A2 (fr) 2009-11-13 2011-05-19 Astrazeneca Ab Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
US8110555B2 (en) 2002-05-03 2012-02-07 Unigen, Inc. 7-hydroxy chromones as potent antioxidants
US8466141B2 (en) * 2005-02-16 2013-06-18 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
KR101302477B1 (ko) 2012-03-02 2013-09-02 경북대학교 산학협력단 스코파론을 유효성분으로 함유하는 암 예방 및 치료용 조성물
WO2013136070A1 (fr) * 2012-03-13 2013-09-19 University Court Of The University Of Dundee Inhibiteur de sik pour l'utilisation dans une méthode de traitement d'un trouble inflammatoire et/ou immunitaire
CN103316025A (zh) * 2013-06-08 2013-09-25 中国人民解放军第二军医大学 对羟基苯乙酮葡萄糖苷在制备抗自身免疫病和抗移植排斥疾病药物中的应用
CN103467428A (zh) * 2013-09-30 2013-12-25 广西南宁百会药业集团有限公司 一种柚皮素的制备方法
WO2014059225A1 (fr) * 2012-10-12 2014-04-17 L'oreal Compositions cosmétiques contenant au moins un flavonoïde et de l'acide férulique
EP2211858B1 (fr) * 2007-10-12 2015-03-25 Politechnika Lodzka Utilisation de sels de pyridinium quaternaire pour inhiber des métastases cancéreuses
CN105326827A (zh) * 2015-11-17 2016-02-17 北京农学院 黄芩素在制备具有抗内毒素活性的药物中的应用
WO2016037171A1 (fr) * 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoïdes inhibiteurs d'il-17a
WO2016149277A1 (fr) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Compositions nutritionnelles pour améliorer la production d'énergie mitochondriale
WO2018015861A1 (fr) * 2016-07-18 2018-01-25 Pharmena S.A. 1-méthylnicotinamide pour le traitement de maladies liées à la protéine c réactive (crp)
US20180099002A1 (en) * 2013-04-09 2018-04-12 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy
KR101855894B1 (ko) * 2016-07-13 2018-05-11 경희대학교 산학협력단 p-coumaric acid를 포함하는 호흡기 질환의 예방 또는 치료 효과를 갖는 약학조성물
CN108586410A (zh) * 2018-06-22 2018-09-28 中国药科大学 一种双黄酮类化合物及其用途
WO2018197461A1 (fr) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh Inhibiteur de parp en combinaison avec un glucocorticoïde et/ou l'acide ascorbique et/ou un facteur de croissance de protéine pour le traitement d'une mauvaise cicatrisation de plaie
CN108956835A (zh) * 2017-05-19 2018-12-07 亚宝药业集团股份有限公司 一种清咽解热口服药物的指纹图谱检测方法
CN109464440A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防肾脏纤维化及慢性肾病的药物中的应用
CN109464441A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用
US10265321B2 (en) 2014-08-08 2019-04-23 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
CN109875977A (zh) * 2019-03-13 2019-06-14 安庆瑄宇医药科技有限公司 一种尼拉帕尼抗癌药物及其制备方法
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3572085A1 (fr) * 2018-05-25 2019-11-27 Neuro-Sys Composition de combinaison synergétique comprenant une saponine stéroïdique, premier composé polyphénolique et éventuellement, second composé polyphénolique
CN110563587A (zh) * 2019-08-28 2019-12-13 哈尔滨医科大学 一种具有抗炎活性的芦荟大黄素琥珀酰酯类化合物及其制备方法和应用
CN111675682A (zh) * 2020-06-30 2020-09-18 海南师范大学 一种苯并吡喃类化合物及其制备方法与应用
US10954242B2 (en) 2016-07-05 2021-03-23 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
WO2021205341A1 (fr) 2020-04-07 2021-10-14 Pharmena S.A. 1-méthylnicotinamide destiné à la prévention/le traitement de maladies inflammatoires des voies respiratoires
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US20220331328A1 (en) * 2021-04-07 2022-10-20 Ingenious Ingredients, LP 1-methylxanthine-based bioactive composition and method of use thereof
WO2023020345A1 (fr) * 2021-08-20 2023-02-23 中国农业科学院郑州果树研究所 COMPOSITION POUR INHIBER L'α-GLUCOSIDASE ET SON UTILISATION
CN115778943A (zh) * 2020-02-26 2023-03-14 上海科技大学 秦皮素在抗冠状病毒中的应用
CN116999391A (zh) * 2023-08-08 2023-11-07 广州沙艾生物科技有限公司 一种car-t细胞制剂及其制备方法和应用
EP4067352A4 (fr) * 2019-11-26 2023-11-29 Benobio Co., Ltd. Nouveau dérivé d'oxydo-réduction de la quercétine et son utilisation en tant qu'inhibiteur de bet
WO2024026109A1 (fr) * 2022-07-28 2024-02-01 Px Ing, Llc Compositions à base de paraxanthine pour inhiber l'inflammation, améliorer la santé articulaire et améliorer la fonction immunitaire

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB717294A (en) * 1952-08-15 1954-10-27 Verdurin Company Process of treating coffee
US4007290A (en) * 1974-01-09 1977-02-08 General Foods Corporation Caffeine antagonim
GB1510583A (en) * 1976-03-26 1978-05-10 Gen Foods Corp Caffeine antagonists
US5145839A (en) * 1988-06-23 1992-09-08 Mirko Beljanski Pharmaceutical composition and method of use
DE4230902A1 (de) * 1992-09-11 1994-03-17 Schaper & Bruemmer Gmbh Verwendung von 5,6-Benzo-alpha-pyron zur Behandlung von chronischer Niereninsuffizienz
CA2127573A1 (fr) * 1994-07-07 1996-01-08 Angela Christine Gedye Traitement vasotonique contre la migraine
WO1997027750A1 (fr) * 1996-02-01 1997-08-07 Anthea Enterprises Incorporated Formes galeniques aqueuses de cafeine
WO1999008601A1 (fr) * 1997-05-05 1999-02-25 Heli Plastic B.V. Systeme de test de diagnostic
WO2002058694A2 (fr) * 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Procede de traitement de tumeurs et de cancers hematologiques
WO2002064090A2 (fr) * 2001-02-14 2002-08-22 Advanced Functional Foods International, Inc. Complement alimentaire permettant d'attenuer les symptomes lies au stress et taux reduits de serotonine
DE10109798A1 (de) * 2001-03-01 2002-09-12 Aventis Pharma Gmbh Gesundheitsfördernde Zusammensetzung von Verbindungen
US20020147152A1 (en) * 2001-02-14 2002-10-10 Functional Foods, Inc. Nutritional supplement for the management of stress
JP2002322055A (ja) * 2001-04-26 2002-11-08 Sanei Gen Ffi Inc デルフィニジン化合物を含有する制癌剤
JP2003159028A (ja) * 2001-11-28 2003-06-03 Hiroshi Suzuki 花粉症治療用食品
US20030158237A1 (en) * 2001-09-04 2003-08-21 Colba R & D Inc. Combination of antioxidant substances for the treatment of alzheimer's disease
WO2003075943A2 (fr) * 2002-03-06 2003-09-18 The Medical Research And Education Trust Compositions d'extrait botanique et procedes d'utilisation
WO2004052294A2 (fr) * 2002-12-06 2004-06-24 Board Of Regents, The University Of Texas System Compositions et methodes associees aux formulations de lipide:emodine
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB717294A (en) * 1952-08-15 1954-10-27 Verdurin Company Process of treating coffee
US4007290A (en) * 1974-01-09 1977-02-08 General Foods Corporation Caffeine antagonim
GB1510583A (en) * 1976-03-26 1978-05-10 Gen Foods Corp Caffeine antagonists
US5145839A (en) * 1988-06-23 1992-09-08 Mirko Beljanski Pharmaceutical composition and method of use
DE4230902A1 (de) * 1992-09-11 1994-03-17 Schaper & Bruemmer Gmbh Verwendung von 5,6-Benzo-alpha-pyron zur Behandlung von chronischer Niereninsuffizienz
CA2127573A1 (fr) * 1994-07-07 1996-01-08 Angela Christine Gedye Traitement vasotonique contre la migraine
WO1997027750A1 (fr) * 1996-02-01 1997-08-07 Anthea Enterprises Incorporated Formes galeniques aqueuses de cafeine
WO1999008601A1 (fr) * 1997-05-05 1999-02-25 Heli Plastic B.V. Systeme de test de diagnostic
WO2002058694A2 (fr) * 2000-11-07 2002-08-01 Dana-Farber Cancer Institute, Inc. Procede de traitement de tumeurs et de cancers hematologiques
WO2002064090A2 (fr) * 2001-02-14 2002-08-22 Advanced Functional Foods International, Inc. Complement alimentaire permettant d'attenuer les symptomes lies au stress et taux reduits de serotonine
US20020147152A1 (en) * 2001-02-14 2002-10-10 Functional Foods, Inc. Nutritional supplement for the management of stress
DE10109798A1 (de) * 2001-03-01 2002-09-12 Aventis Pharma Gmbh Gesundheitsfördernde Zusammensetzung von Verbindungen
JP2002322055A (ja) * 2001-04-26 2002-11-08 Sanei Gen Ffi Inc デルフィニジン化合物を含有する制癌剤
US20030158237A1 (en) * 2001-09-04 2003-08-21 Colba R & D Inc. Combination of antioxidant substances for the treatment of alzheimer's disease
JP2003159028A (ja) * 2001-11-28 2003-06-03 Hiroshi Suzuki 花粉症治療用食品
WO2003075943A2 (fr) * 2002-03-06 2003-09-18 The Medical Research And Education Trust Compositions d'extrait botanique et procedes d'utilisation
WO2004052294A2 (fr) * 2002-12-06 2004-06-24 Board Of Regents, The University Of Texas System Compositions et methodes associees aux formulations de lipide:emodine
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 03 5 May 2003 (2003-05-05) *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 10 8 October 2003 (2003-10-08) *

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110555B2 (en) 2002-05-03 2012-02-07 Unigen, Inc. 7-hydroxy chromones as potent antioxidants
US9078891B2 (en) 2002-05-03 2015-07-14 Unigen, Inc. 7-hydroxy chromones as potent antioxidants
WO2006042441A3 (fr) * 2004-10-22 2006-07-13 Dsm Ip Assets Bv Nouveaux agents de prevention et de traitement de troubles associes a une neurotransmission deficiente
WO2006042441A2 (fr) * 2004-10-22 2006-04-27 Dsm Ip Assets B.V. Nouveaux agents de prevention et de traitement de troubles associes a une neurotransmission deficiente
US8044094B2 (en) 2004-10-22 2011-10-25 Dsm Ip Assets B.V. Agents for preventing and treating disorders connected to impaired neurotransmission
US9066922B2 (en) 2005-02-16 2015-06-30 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
US8466141B2 (en) * 2005-02-16 2013-06-18 Md Bioalpha Co., Ltd. Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
WO2007132893A1 (fr) * 2006-05-17 2007-11-22 Arkray, Inc. Suppresseur d'expression de mcp-1 et agent d'amélioration des maladies inflammatoires, produit pharmaceutique, complément, aliment, boisson ou additif alimentaire comprenant ledit suppresseur
JPWO2007132893A1 (ja) * 2006-05-17 2009-09-24 アークレイ株式会社 Ｍｃｐ−１の発現抑制剤、それを用いた炎症性疾患の改善剤、医薬品、サプリメント、食品、飲料および食品添加剤
WO2008012666A3 (fr) * 2006-07-28 2008-09-04 Indena Spa Procédés de traitement et de prévention d'une mucite
US9730952B2 (en) 2006-07-28 2017-08-15 Indena S.P.A. Methods for treating and preventing mucositis
AU2007278959B2 (en) * 2006-07-28 2013-03-28 Indena S.P.A. Treatment and prevention mucositis by anthocyanidin derivatives
US9289412B2 (en) 2006-08-11 2016-03-22 The Johns Hopkins University Role of limonoid compounds as neuroprotective agents
EP2056818A2 (fr) * 2006-08-11 2009-05-13 The Johns Hopkins University Compositions et méthodes de neuroprotection
EP2056818A4 (fr) * 2006-08-11 2009-09-23 Univ Johns Hopkins Compositions et méthodes de neuroprotection
WO2008021368A2 (fr) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions et méthodes de neuroprotection
JP2010501590A (ja) * 2006-08-23 2010-01-21 アメリカ合衆国 酸化的ストレス関連疾患の治療または予防方法
WO2008024893A2 (fr) * 2006-08-23 2008-02-28 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procédé de traitement ou de prévention d'une maladie associée au stress oxydatif
EP2617424A3 (fr) * 2006-08-23 2014-05-07 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Dérivatives d'acide urique ou d'acide thiourique pour traitement des maladies associée au stress oxydatif
WO2008024893A3 (fr) * 2006-08-23 2009-03-05 Us Gov Health & Human Serv Procédé de traitement ou de prévention d'une maladie associée au stress oxydatif
JP2008120729A (ja) * 2006-11-13 2008-05-29 Kao Corp Ｆｘｒ活性化剤
AU2008204909B2 (en) * 2007-01-09 2013-05-30 Unigen, Inc. Chromones as therapeutic agents
WO2008086403A1 (fr) * 2007-01-09 2008-07-17 Unigen Pharmaceuticals, Inc. Chromones utilisées comme agents thérapeutiques
CN101631544B (zh) * 2007-01-09 2015-11-25 尤尼根制药公司 作为治疗剂的色酮
US8852657B2 (en) 2007-01-09 2014-10-07 Unigen, Inc. Chromones as therapeutic agents
US8377972B2 (en) 2007-02-28 2013-02-19 Trigendo Sp. zo.o. Use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
WO2008104920A1 (fr) * 2007-02-28 2008-09-04 Trigendo Sp. Z O.O. Utilisation de composés de pyridinium quaternaires pour la vasoprotection et/ou l'hépatoprotection
RU2477132C2 (ru) * 2007-02-28 2013-03-10 Хепендо Сп. З.О.О. Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции
US7893095B2 (en) 2007-02-28 2011-02-22 Trigendo Sp. Z O.O. Use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
US8198319B2 (en) 2007-03-19 2012-06-12 Milton Joseph Ahrens Composition and method for treating diabetes and metabolic disorders
US7943164B2 (en) 2007-03-19 2011-05-17 Milton Joseph Ahrens Composition and method for treating diabetes and metabolic disorders
WO2008115723A1 (fr) 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition et procédé pour le traitement du diabète et de perturbations du métabolisme
JP2010522185A (ja) * 2007-03-19 2010-07-01 エーティーエム メタボリックス エルエルエルピー 糖尿病および代謝障害を治療するためのクエルセチン、ミリセチンおよびクロロゲン酸の組成物
EP2211858B1 (fr) * 2007-10-12 2015-03-25 Politechnika Lodzka Utilisation de sels de pyridinium quaternaire pour inhiber des métastases cancéreuses
WO2010066641A1 (fr) * 2008-12-11 2010-06-17 Unilever Plc Composition orale
US8546445B2 (en) 2008-12-11 2013-10-01 Conopco, Inc. Oral composition
CN102245177A (zh) * 2008-12-11 2011-11-16 荷兰联合利华有限公司 口服组合物
EP2243474A1 (fr) * 2009-04-23 2010-10-27 King Saud University Effet prospectif de thymoquinome dans la sepsie
US8895625B2 (en) 2009-04-23 2014-11-25 King Saud University Protective effect of thymoquinone in sepsis
WO2011058367A2 (fr) 2009-11-13 2011-05-19 Astrazeneca Ab Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
CN101991566A (zh) * 2010-11-26 2011-03-30 中国人民解放军第二军医大学 落叶松脂醇在制备抗自身免疫病和抗移植排斥疾病药物中的应用
KR101302477B1 (ko) 2012-03-02 2013-09-02 경북대학교 산학협력단 스코파론을 유효성분으로 함유하는 암 예방 및 치료용 조성물
US9670165B2 (en) 2012-03-13 2017-06-06 Dana-Farber Cancer Institute, Inc. SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder
US10233157B2 (en) 2012-03-13 2019-03-19 Dana-Farber Cancer Institute, Inc. SIK inhibitor for use in a method of treating an inflammatory and/or immune disorder
WO2013136070A1 (fr) * 2012-03-13 2013-09-19 University Court Of The University Of Dundee Inhibiteur de sik pour l'utilisation dans une méthode de traitement d'un trouble inflammatoire et/ou immunitaire
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
WO2014059225A1 (fr) * 2012-10-12 2014-04-17 L'oreal Compositions cosmétiques contenant au moins un flavonoïde et de l'acide férulique
US10576096B2 (en) * 2013-04-09 2020-03-03 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy
US20180099002A1 (en) * 2013-04-09 2018-04-12 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy
CN103316025A (zh) * 2013-06-08 2013-09-25 中国人民解放军第二军医大学 对羟基苯乙酮葡萄糖苷在制备抗自身免疫病和抗移植排斥疾病药物中的应用
CN103467428B (zh) * 2013-09-30 2016-04-06 广西南宁百会药业集团有限公司 一种柚皮素的制备方法
CN103467428A (zh) * 2013-09-30 2013-12-25 广西南宁百会药业集团有限公司 一种柚皮素的制备方法
US10975058B2 (en) 2014-07-21 2021-04-13 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10265321B2 (en) 2014-08-08 2019-04-23 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (SIK) inhibitors
WO2016037171A1 (fr) * 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoïdes inhibiteurs d'il-17a
US10385034B2 (en) 2014-09-05 2019-08-20 The Cleveland Clinic Foundation Flavonoid IL-17A inhibitors
WO2016149277A1 (fr) * 2015-03-17 2016-09-22 Specialty Nutrition Group, Inc. Compositions nutritionnelles pour améliorer la production d'énergie mitochondriale
CN105326827A (zh) * 2015-11-17 2016-02-17 北京农学院 黄芩素在制备具有抗内毒素活性的药物中的应用
US10954242B2 (en) 2016-07-05 2021-03-23 The Broad Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11725011B2 (en) 2016-07-05 2023-08-15 The General Hospital Corporation Bicyclic urea kinase inhibitors and uses thereof
KR101855894B1 (ko) * 2016-07-13 2018-05-11 경희대학교 산학협력단 p-coumaric acid를 포함하는 호흡기 질환의 예방 또는 치료 효과를 갖는 약학조성물
AU2017298648B2 (en) * 2016-07-18 2023-05-11 Pharmena S.A. 1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
CN109562108A (zh) * 2016-07-18 2019-04-02 法米娜生物技术公司 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺
WO2018015861A1 (fr) * 2016-07-18 2018-01-25 Pharmena S.A. 1-méthylnicotinamide pour le traitement de maladies liées à la protéine c réactive (crp)
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
US11878019B2 (en) 2017-02-28 2024-01-23 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
WO2018197461A1 (fr) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh Inhibiteur de parp en combinaison avec un glucocorticoïde et/ou l'acide ascorbique et/ou un facteur de croissance de protéine pour le traitement d'une mauvaise cicatrisation de plaie
CN108956835A (zh) * 2017-05-19 2018-12-07 亚宝药业集团股份有限公司 一种清咽解热口服药物的指纹图谱检测方法
WO2019224388A1 (fr) * 2018-05-25 2019-11-28 Neuralia Composition de combinaison synergétique comprenant une saponine stéroïdienne, un premier composé polyphénolique et un second composé polyphénolique
US11951113B2 (en) 2018-05-25 2024-04-09 Neuralia Synergestic combination composition comprising a steroidal saponin, a first polyphenolic compound and a second polyphenolic compound
EP3572085A1 (fr) * 2018-05-25 2019-11-27 Neuro-Sys Composition de combinaison synergétique comprenant une saponine stéroïdique, premier composé polyphénolique et éventuellement, second composé polyphénolique
CN108586410B (zh) * 2018-06-22 2020-06-23 中国药科大学 一种双黄酮类化合物及其用途
CN108586410A (zh) * 2018-06-22 2018-09-28 中国药科大学 一种双黄酮类化合物及其用途
CN109464441A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用
CN109464440A (zh) * 2019-01-17 2019-03-15 北京大学 3-乙酰氨基香豆素在制备治疗或预防肾脏纤维化及慢性肾病的药物中的应用
CN109464441B (zh) * 2019-01-17 2021-04-23 北京大学 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用
CN109875977A (zh) * 2019-03-13 2019-06-14 安庆瑄宇医药科技有限公司 一种尼拉帕尼抗癌药物及其制备方法
CN110563587A (zh) * 2019-08-28 2019-12-13 哈尔滨医科大学 一种具有抗炎活性的芦荟大黄素琥珀酰酯类化合物及其制备方法和应用
CN110563587B (zh) * 2019-08-28 2021-11-02 哈尔滨医科大学 一种具有抗炎活性的芦荟大黄素琥珀酰酯类化合物及其制备方法和应用
EP4067352A4 (fr) * 2019-11-26 2023-11-29 Benobio Co., Ltd. Nouveau dérivé d'oxydo-réduction de la quercétine et son utilisation en tant qu'inhibiteur de bet
CN115778943A (zh) * 2020-02-26 2023-03-14 上海科技大学 秦皮素在抗冠状病毒中的应用
CN115778943B (zh) * 2020-02-26 2023-11-10 上海科技大学 秦皮素在抗冠状病毒中的应用
WO2021205341A1 (fr) 2020-04-07 2021-10-14 Pharmena S.A. 1-méthylnicotinamide destiné à la prévention/le traitement de maladies inflammatoires des voies respiratoires
CN111675682A (zh) * 2020-06-30 2020-09-18 海南师范大学 一种苯并吡喃类化合物及其制备方法与应用
US20220331328A1 (en) * 2021-04-07 2022-10-20 Ingenious Ingredients, LP 1-methylxanthine-based bioactive composition and method of use thereof
US11753388B2 (en) 2021-08-20 2023-09-12 Zhengzhou Fruit Research Institute, Chinese Academy Of Agricultural Sciences Composition for inhibiting alpha-glucosidase and application thereof
WO2023020345A1 (fr) * 2021-08-20 2023-02-23 中国农业科学院郑州果树研究所 COMPOSITION POUR INHIBER L'α-GLUCOSIDASE ET SON UTILISATION
WO2024026109A1 (fr) * 2022-07-28 2024-02-01 Px Ing, Llc Compositions à base de paraxanthine pour inhiber l'inflammation, améliorer la santé articulaire et améliorer la fonction immunitaire
CN116999391A (zh) * 2023-08-08 2023-11-07 广州沙艾生物科技有限公司 一种car-t细胞制剂及其制备方法和应用

Similar Documents

Publication Publication Date Title
WO2006024545A1 (fr) Composes bicycliques naturels condenses et utilisation de ceux-ci comme inhibiteurs de parp et des processus inflammatoires a mediation parp
Cao et al. The antihypertensive potential of flavonoids from Chinese Herbal Medicine: A review
AU2015246090B2 (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US8221804B2 (en) Compositions and methods for enhancing cognitive function
US7923041B2 (en) Compositions and methods for enhancing cognitive function
ES2246845T3 (es) Composicion para la prevencion o el tratamiento de la demencia que comprende un derivado del acido hidroxicinamico o un extracto de una planta del genero angelicae que lo contenga.
CA2549443A1 (fr) Supplements dietetiques pour provoquer une perte de poids rapide, ameliorer le niveau d'energie le jour, faciliter la relaxation et le sommeil la nuit, reguler l'appetit ou accroitre le metabolisme
CN109432096B (zh) 盐酸去亚甲基四氢小檗碱在制备预防或治疗酒精性肝病和非酒精性脂肪肝病药物中的应用
KR20070008230A (ko) 향나무 추출물 또는 세드롤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
JP2019019142A (ja) Ｖｃａｍ−１発現抑制剤
KR100610562B1 (ko) 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물
TWI472335B (zh) 用以治療腸激躁症之山薑屬植物萃取物
JP2006342103A (ja) ウーロン茶葉抽出物ｏｔａｃを有効成分とする発癌抑制剤
JP4176638B2 (ja) 川椒抽出物を含む脳細胞保護及び記憶力増進用組成物
KR20080032494A (ko) 대황 추출물 또는 이로부터 분리된 피시온 화합물을유효성분으로 함유하는 인지 기능 장애의 예방 또는 치료용조성물
US20090214682A1 (en) Composition and methods for weight loss in a subject
KR20100040281A (ko) 실로스타졸과 은행잎 추출물을 함유한 약제 조성물
KR20210090543A (ko) 커피 실버스킨 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 근육질환의 예방 또는 치료용 조성물
KR101916909B1 (ko) 혈관 내피세포의 기능장애 개선용 조성물
JP6627141B2 (ja) ベニバナボロギク抽出物を調製する方法、それにより調製された抽出物、及び抽出物の使用
KR102206831B1 (ko) 메로터페노이드계 화합물 및 그의 용도
KR101815660B1 (ko) 황칠나무 잎 추출물의 분획물을 유효성분으로 함유하는 당뇨에 의해 저하된 인지기능 또는 기억능력 개선용 조성물
KR100739280B1 (ko) 운남 홍두삼 유래 이소탁시레시놀을 성분으로 하는골다공증 치료ㆍ예방약
KR20120080672A (ko) 관동화 추출물을 포함하는 백혈병 치료용 조성물 및 건강 기능성 식품
JP2020124191A (ja) 二日酔い解消用の組成物およびその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase